Opinion|Videos|January 30, 2025
Imlunestrant Clinical Data: Insights From the EMBER and EMBER-3 Trials
Author(s)Katherine Clifton, MD, Shipra Gandhi, MD
Dr. Clifton and Dr. Gandhi review the EMBER trial program, discussing study designs, key findings from phase 1b and EMBER-3 trials of imlunestrant-based combinations, and insights into efficacy, safety, and subgroup outcomes in estrogen receptor–positive/HER2-negative (ER+/HER2–) advanced breast cancer (ABC).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please provide an overview of the EMBER trial study design, arms, and high-level takeaways from the following:
- EMBER phase 1b: imlunestrant plus or minus everolimus or alpelisib
- EMBER phase 1b: imlunestrant plus abemaciclib plus or minus aromatase inhibitor
- Please provide some background on the EMBER-3 trial investigating imlunestrant plus or minus abemaciclib in ER+/HER2– ABC pretreated with endocrine therapy plus or minus CDK4/6 inhibitor.
- Please provide an overview of major efficacy and safety end points from EMBER-3 as well as subgroup data from the trial.
Advertisement
Related to this article
T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
3
Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management
4
The OncFive: Top Oncology Articles for the Week of 8/30
5